Pharma Focus Asia

Pfizer to invest $200 Million for New Biologics Clinical Manufacturing Facility in Andover, Massachusetts


Pfizer Inc. broke ground for its new biologics clinical manufacturing facility in Andover, Massachusetts with an investment of $200 Million.


The New 175,000 sq. ft. state-of-the-art facility that will enable the production of high-quality, complex biologics and vaccines. The new 5-story building is expected to be operational by January 2019. Approximately 75 new employees will be hired to support clinical manufacturing. In addition to the Andover campus, Massachusetts is home to Pfizer’s Research and Development hub in Cambridge. Pfizer has approximately 2,000 employees based in Massachusetts.

The new clinical manufacturing facility is designed with 5 independent manufacturing suites to support Pfizer’s highly complex and diverse biologics research effort. The facility will:

•   Employ flexible design to fully enable Next Generation Manufacturing strategies.
•   Leverage state-of-the-art single-use bioreactors and disposable process technologies.
•   Provide clinical manufacturing options with the lowest cost and greatest flexibility for efficiently driving important clinical drugs to patients.


NamePfizer Inc.
LocationAndover, Massachusetts
TypeNew Biologics Clinical Manufacturing Facility
Estimated Cost$200 Million
Operational ByJanuary 2019
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference